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drug therapy use in a practice setting in patients who did or didn’t receive the 
assay. Methods: Patients with initial visits for ER+, HER2- ESBC to the Regional 
Cancer Care Associates physician practice in 2009-2013 were identified using COTA, 
an oncology outcomes and cost tracking database. A case-control design was used to 
describe demographic, clinical, adjuvant CT, and supportive care therapy informa-
tion for patients < 70 years. Results: 158 Case patients who received the assay 
and 111 Controls who did not were identified. Cases were older, had larger tumors, 
and had more stage 1 tumors (p < 0.05). A significantly lower proportion in the 
Case group (21%) received CT compared to the Control group (56%; p< 0.001). The 
proportions of N- Case patients who received CT were 2%, 33%, and 100% in the 
Low, Intermediate and High Recurrence Score groups, respectively. Fifty of the 269 
patients (10 Cases, 40 Controls) were N+. In N+ Cases (n = 10), no Low risk group 
patients (n= 6) received CT, while all Intermediate and High risk group patients 
did. The proportion of Case patients who received pegfilgrastim or aprepitant was 
significantly lower than in the Control group (p< 0.001). The proportions of N+ Case 
patients receiving pegfilgrastim or aprepitant were also lower than in the N+ Control 
group. ConClusions: Physicians appear to be selective in using the 21-Gene assay 
in ESBC patients. Tested patients were less likely to receive CT and other supportive 
therapies. A majority of N+ patients tested had low Recurrence Score results and 
avoided CT, supporting potential utility of the assay in these patients.
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objeCtives: Assess the trends in Human Epidermal Growth Factor Receptor 2 
(HER2), Epidermal Growth Factor Receptor mutation (EGFRm) and KRAS biomarker 
testing in BC, mNSCLC and mCRC respectively in EU. Methods: A multi-country 
retrospective medical chart-review of BC/mNSCLC/mCRC patients were conducted 
by cancer treating physicians in Germany/France/Spain/Italy (4EU) and the UK; 
Data collection period was BC:2004-2013, mNSCLC/mCRC:2009-2014. Physicians 
were recruited from a geographically representative sample in each country. 
Approximately 10-25 eligible patients in respective tumor types on usual care 
anti-cancer regimen were identified by each physician within each of the four-
quarterly study observation-windows in respective years. Physicians abstracted 
data on patient demographics, disease status, treatment patterns and biomarker 
status .The analysis focused on HER2, EGFRm and KRAS testing trends. Results: 
An average of 7500 BC (4EU~6000; UK~1500), 3600 mNSCLC (4EU~3000; UK~600) and 
750 mCRC (4EU~600; UK~150) patient charts were abstracted per year. Percentage BC 
patients tested for HER2 increased in 4EU from 2004(70%) to 2009(89%) to 2013(97%), 
while the testing rates started relatively low in the UK initially (2004:23%; 2009:81%) 
and reached 4EU levels in 2013 (98%). EGFRm testing rates in mNSCLC increased 
in 4EU from December-2009(7%) to December-2011(53%) to December-2013(62%), 
and the UK testing rates increased during the corresponding period to be on-par 
despite starting slow (December-2009:2%; December-2011:33%; December-2013:62%). 
KRAS mutation testing rates in mCRC showed the largest difference between 
4EU (December-2009:61%; December-2011:89%; December-2013:92%) and UK 
(December-2009:6%; December-2011:26%; December-2013:62%) throughout the 
evaluation period. ConClusions: HER2/EGFRm/KRAS biomarker testing rates 
initially lagged behind in the UK in comparison to Germany/France/Italy/Spain, 
and the difference existed throughout the study evaluation period for KRAS, while 
HER2/EGFRm testing rates converged in 2013. Factors influencing these observed 
patterns (incl. access to medicines with relevant indications) needs further scru-
tiny to facilitate optimal care delivery utilizing targeted oncology therapeutics to 
benefit patients.
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objeCtives: In response to increased pressure to contain costs and optimize 
patient outcomes, hospitals have implemented standardized decision-making 
processes utilizing value analysis committees (VACs). In 2012, 64% of hospitals 
reported using some form of VAC. The objective of this analysis was to quantify 
the adoption of VAC, the product features considered impactful by VAC, timing 
of review and evidence requirements. Methods: Qualitative interviews (n= 40) 
and quantitative online survey (n= 76) were conducted with C-suite executives, 
purchasers, and clinician leads in the second half of 2014. Research participants 
were drawn from across the US, from a diverse selection of hospitals, including 
large/small, rural/urban and profit/non-profit. Outcomes of the research included 
adoption of VAC, triggers for VAC review, timing of review process, evidence 
requirements and implications for medical device companies. Results: 100% 
of hospitals surveyed report use of VAC for all new products being considered. 
Existing products may undergo a VAC when price or features change. Most prod-
ucts are brought to the VAC by the service line head, although one third of hospitals 
reported use of an automated system. Price of the product was identified as the 
most important consideration during VAC, though patient experience and other 
elements addressed by value-based purchasing were also mentioned. Clinical trial 
data was cited as most influential. However, most hospitals consider products in 
terms of their patient populations and specific context, making clinical trial data 
not optimally relevant to all hospitals. ConClusions: Because VACs are now a 
standard process at US hospitals, medical device companies must have a thorough 
understanding of the process and evidence requirements. Opportunities exist 
for increased communication between innovators and hospital decision-makers 
to align solutions with needs.Facility specific value propositions and data are 
frequently required to secure product approval.
in small populations but were not yet ready to make formal coverage decisions or 
support widespread adoption of specific technologies. Most payers were optimis-
tic about the promise of digital health solutions, with the greatest expectations 
for chronic disease management. Skepticism about incremental value and costs 
led most respondents to desire stringent evaluation criteria and evidence stand-
ards, with standard benchmarks of value preferred. Most expected digital health 
solutions would need to demonstrate decreased costs and improved clinical out-
comes. The most commonly desired attributes of digital health technologies are 
randomized clinical trial results, proven patient compliance, and EHR/EMR integra-
tion. ConClusions: Developing standardized evaluation criteria for digital health 
technologies will drive more consistent coverage outcomes and facilitate faster 
patient access to novel digital health technologies.
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objeCtives: Companion devices enable Mobile Health (mHealth) via remote moni-
toring of patients’ biometrics. By 2020, the global mHealth market is estimated to 
reach $6.28 billion. While mHealth is expected to revolutionize delivery of patient 
care, especially for chronic diseases such as diabetes or asthma, it has not realized 
its full potential. To that end, the objectives of this study were to: 1) Characterize 
benefits that companion devices may deliver to key stakeholders, including patients, 
Health Care Professionals (HCPs), payers, and drug manufacturers; 2) Determine how 
HCPs currently utilize companion devices and key unmet needs; 3) Identify perceived 
roadblocks by payers in coverage & reimbursement of companion devices. Methods: 
Health Technology Assessments (HTAs) and guidelines published between 2010 and 
2014, and publications archived in MEDLINE and PubMed were analyzed to assess 
potential benefits, challenges, and historical valuation of companion devices. 
Additionally, approved companion devices were evaluated to assess their coverage 
and reimbursement and associated evidence requirements in the US and 5 major 
EU markets. Results: Companion devices can potentially deliver benefits across 
the continuum of care that may be categorized into three areas: patient manage-
ment (adherence and compliance), disease management (clinic visits and trend 
alerts), drug management (dosage and clinical events). Current barriers to adoption 
appear to be primarily cost of technology, potentially increased liability exposure, 
compliance with patient confidentiality, challenge in demonstrating positive budget 
impact, and importantly, lack of optimal reimbursement (separate vs bundled pay-
ment). ConClusions: While relatively nascent, companion devices are expected to 
play a role along the full continuum of patient care: from prevention, diagnosis, treat-
ment, to monitoring. As such, this study indicated that the integration of companion 
devices with care plans is potentially hinged around three key issues: a) patient edu-
cation and awareness, b) physician engagement via streamlined clinical workflow, 
and c) demonstration of long-term economic benefits to payers.
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objeCtives: Pregnancy poses a high risk of thyroid dysfunction (TD) causing 
adverse outcomes in mother, fetus and neonate. This makes screening pregnant 
women for TD essential. Universal screening (US) aims to screen all women in 
contrast to targeted screening (TS) where only women at high-risk get tested for TD 
during pregnancy. Existing guidelines do not recommend US. Thus we performed 
meta-analysis to clarify this moot question whether US should be recommended 
for screening TD in pregnancy. Methods: All original research articles compar-
ing the two approaches to detect TD in pregnancy were searched from databases 
PubMed, EBSCO and Cochrane library. Effect estimate is reported as loss ratio (LR) 
signifying missed cases. Missed cases are women considered as low risk during TS. 
Subgroup analysis was done for hyperthyroid and overall thyroid disorder. Further 
sensitivity and specificity analysis was also done. Data is analyzed using CMA 
2.0. Results: Total of 9 studies including 10,888 women was included in present 
analysis. As significant heterogeneity was found between studies (P ‹ 0.001, I2 = 
0.99), random-effects model was used. 46% hypothyroid cases were missed if TS 
was performed instead of US (RR 0.46 (95% CI (0.35 to 0.61), P ≤ 0.001). Sensitivity 
analyses showed (RR 0.40 (95% CI (0.27 to 0 0.55), P≤ 0.001) Specificity test has 
confirmed it (RR 0.31 (95% CI (0.20 to 0.47), P≤ 0.001). Similar trends were seen in 
hyperthyroid (RR 0.56 (95% CI (0.51 to 0.65), P≤ 0.001) and over-all TD (RR 0.49 (95% 
CI (0.43 to 0.60), P≤ 0.001). ConClusions: Almost half of the cases were missed 
on TS. The present pooled analysis recommends US to identify overall TD as well 
as hypothyroid cases in pregnancy. This serves as a strong evidence for inclusion 
of US into guidelines.
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objeCtives: Patients with low risk 21-Gene Breast Cancer Assay results can safely 
avoid chemotherapy (CT), as has been shown in protocol-driven studies. This study’s 
objective was to compare, using practice management data, CT and supportive 
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services. For the 2012 sample, it is possible that MCBS beneficiaries might have used 
preventive screening within the previous year which resulted in underutilization 
of those services in 2012. Further research should extend the period of analysis to 
investigate whether observed decrease remains unchanged over time.
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objeCtives: Colorectal cancer (CRC) is largely preventable using screening to detect 
and remove adenomatous polyps during flexible sigmoidoscopy (FS) and colonos-
copy, or to identify early-stage cancers with fecal occult blood testing (FOBT) and 
fecal immunochemical testing (FIT). Despite the proven efficacy of CRC screen-
ing (CRCS), screening rates remain relatively low. Patient’s psychological barriers 
seem to affect participation in CRCS. We conducted a comprehensive review of the 
literature to identify psychological barriers associated with CRCS. Methods: We 
conducted a systematic review of studies reporting on psychological factors and 
colorectal cancer screening from 2004 to 2014 using MEDLINE/PubMed and Google 
Scholar. Limiting the search to the English language reports, the search strategy 
involved combining (a) colorectal cancer screening-related key words (eg, ‘‘cancer,’’ 
‘‘screening,’’ ‘‘adherence,’’ ‘‘colonoscopy,’’ ‘‘sigmoidoscopy,’’ ‘‘chemotherapy’’) and 
(b) words pertaining to or synonymous with fear (eg, ‘‘fear,’’ ‘‘anxiety,’’ ‘‘embarrass-
ment,’’ ‘‘belief). Results: Of the 17 articles identified, 11 explored general barri-
ers among the U.S. population, while the other 6 examined specific barriers such 
as fear, disgust, perceptions, attitudes, knowledge, and medical mistrust. Six of 
the studies were qualitative studies, 4 were quantitative study, 3 used a mixed 
methods approach and 4 were reviews. Sample sizes varied from 23-55 subjects in 
the qualitative studies; and 151-454 subjects in the quantitative studies. Common 
perceived barriers included mistrust of the healthcare system, embarrassment of 
being undressed in front of a provider, the nature of the screening exam itself, 
fear of being a burden to the family, and fatalism. ConClusions: The results of 
this study demonstrate that psychological factors such as fear of the test itself, of 
cancer diagnosis, of burdening family members, and embarrassment play a role in 
determining whether patients would opt for CRCS. In order to improve the quality 
of care and successfully increase screening rates for CRC, overcoming these barriers 
is of utmost importance.
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objeCtives: ST-segment elevation myocardial infarction (STEMI) is a leading cause 
of global morbidity and mortality, comprising 25-40% of MI presentations, with vary-
ing outcomes. 5-6% of patients die before leaving hospital, and 7-18% of discharged 
patients die within one year. In Romania, the annual mortality rate is 14.5% for admit-
ted patients. An Excel-based model was developed to assess the clinical and economic 
impact of different treatment strategies for STEMI patients in Romania. Methods: 
This model uses data from the Romanian National Registry, Romanian Heart 
Foundation, and CC Iliescu Heart Institute to evaluate STEMI treatment scenarios 
based on disease awareness, timely hospital admissions, and treatment with PCI, 
versus alternative approaches such as thrombolytics or no reperfusion. 2009-2014 
outcomes were modeled year-over-year for sequential STEMI cohorts. Prospective 
outcomes through 2019 were modeled to calculate the value of continued invest-
ment in STEMI management. Model inputs included morbidity and mortality, labor 
productivity (measured by average wage), direct treatment costs, and disease burden 
(measured by disability-adjusted life-years and value of a statistical life). Outputs 
were calculated up to one year after initial STEMI event, and calculated separately 
for hospital-admitted and non-admitted populations, with the latter group divided 
by treatment pathway: PCI, thrombolytics, no reperfusion, or CABG. Results: From 
2009-2014, an investment of 20.8 million € in interventional cardiology and catheteri-
zation laboratories resulted in 2,197 lives saved, with cost savings of 21.6 million € 
from improved productivity. Prospective calculations through 2019 show an invest-
ment of 14.2 million € would result in 1,528 lives saved, with cost savings of 12.3 
million € . ConClusions: From 2009-2014, Romanian healthcare expenditures to 
improve STEMI management strategies showed favorable clinical outcomes when 
more patients were managed with PCI. This mortality reduction suggests that con-
tinued national investment in STEMI management could further improve these rates, 
with greater cost savings achieved as a result.
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objeCtives: Use of operating rooms (OR) in hospitals contributes significantly to the 
total cost of inpatient care. Autologous fat grafting (AFG) is a process of re-injecting 
a patient’s own fat to treat soft tissue defects in surgeries. The objective was to com-
pare the impact of a new AFG system, Revolve versus centrifugation on OR time and 
costs. Methods: Data from literature, conference posters and surgeon survey (n= 30) 
were used. Cost of OR included staff wages and facility costs, and adjusted for inflation 
to 2014 USD. Mean time of completing AFG was estimated using rate and volume of fat 
injected reported in posters. Inputs required for projection such as mean number of 
AFG procedures per year for a hospital were obtained from survey. Per case incremen-
tal differences in OR cost for Revolve versus centrifugation was estimated by dividing 
volume of fat injected by rate of AFG and multiplying by OR cost prior to subtracting 
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objeCtives: During 2013, Argentina (AR) suffered severe currency depreciation (above 
32%) and an annual inflation rate of 28%. Increases in imported medical devices’ 
prices (MDs) plus a weakened AR peso might have impacted their access. The objective 
of this research was to evaluate the impact of the 2013 Argentinian economic crisis in 
the healthcare (HC) sector and the access of imported medical devices. Methods: 
Specific analysis to evaluate MDs’ cost in HC system (private payers and provid-
ers) was performed. Primary cost information was obtained and analyzed from the 
HC System and ADECRA (Argentinian Healthcare Private Providers Association). 
The information includes inflation-adjusted costs incurred by the provision of HC 
services (labor costs, medical and non-medical supplies, among others). From the 
manufacturer perspective, the mean percentage of MDs’ price increase and the sales 
amount of implantable joints prosthesis were considered and compared both in local 
currency and USD. Results: During 2013, the government allowed private payers 
to increase their fees by 25.5%. As a consequence, labor costs increased by 25.7%, 
affecting private payers and providers. For private healthcare providers, the cost to 
deliver care rose to 26.9%, whereas medical supplies and devices’ increase was 33.4%. 
Manufacturers raised their prices in 22%, while their sales rose in 28% in local cur-
rency, but only 5% in USD. ConClusions: 2013 AR crisis affected the HC system. HC 
providers were mainly harmed as the result of price increases for MDs and supplies 
above the increase of its charges (services fees paid by the private system) and even 
below the ADECRA index (30%), which rose up to 200% compared to 2010. This repre-
sents a burden for payers, who had to absorb the price increase for the high cost of 
imported MDs in order to provide access to their population.
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objeCtives: Abnormal uterine bleeding (AUB) is an increasingly frequent complaint 
of women visiting gynecologists’ offices. Uterine polyps, a common etiology, are 
traditionally removed in hospitals or ambulatory surgery centers (ASCs). A mini-
mally invasive hysteroscopic tissue removal system (TRUCLEAR™, Smith&Nephew) 
(HTRS) allows a shift of care site to office hysteroscopy (OH) with at least equal 
effectiveness plus increased patient convenience and safety. Current procedural 
coding does not allow offices to bill payers for HTRS so OH using HTRS loses money. 
HTRS advantages include patients are seen and treated during a single office visit, 
experience shorter procedure times, may avoid preliminary medications and gen-
eral anesthesia, and return to activity sooner. Patient and payer expenses could be 
reduced because overall costs of an office procedure are lower than those performed 
at hospitals or ASCs. Methods: A mutually beneficial OH fee schedule for patients, 
offices and Blue Cross and Blue Shield of North Carolina (BCBS-NC) was determined. 
A global procedure fee estimated frequency of use of HTRS devices during OH. 
Immediate treatment also avoids the need to schedule treatment at a later time in 
the hospital or ASC. Avoiding the higher overhead charges of hospitals or ASCs for 
staff, operating and recovery rooms, plus general anesthesia allowed an increase in 
office reimbursement that offset HTRS cost while BCBS-NC realized a net reduction 
in overall payments. Results: A pilot program in October 2013 – November 2014 
increased allowable OH charges resulting in about $1500 higher payment for OH 
with estimated per procedure savings of as much as nearly $2000 for patients, from 
lower insurance deductibles, and $2800 to BCBS-NC compared to what they would 
have paid for the procedure in a hospital or ASC. ConClusions: Shifting the site 
of service through payment modification allowed all stakeholders to benefit from 
improved financial and clinical outcomes.
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objeCtives: During the last 30 years, a significant decrease in annual cancer inci-
dence rates was noted for colon and rectum, largely attributable to the utilization 
of colorectal screening services. This trend accelerated in recent years as these tests 
allow a doctor to localize and remove polyps of a precancerous character. The U.S. 
Preventive Services Task Force assigned grade A recommendation for colorectal 
screening beginning at age 50 and continuing until age 75 years. Moreover, the 
adoption of Patient Protection and Affordable Care Act resulted in an increased 
access to preventive services by eliminating all cost-sharing for colorectal screen-
ing among Medicare beneficiaries effective January 2011. The aim of this study is 
to investigate whether the new policy had an impact on the utilization of colorec-
tal screening among Medicare beneficiaries after January 2011. Methods: This 
study used Medicare Current Beneficiary Survey (MCBS) Access to Care and Cost 
and Use files for years 2009 and 2011. Both community-dwelling and institution-
alized Medicare beneficiaries between 50 and 75 years of age were included into 
the study. Beneficiaries who underwent colectomy or who had colorectal cancer 
in any period included in the analysis were excluded. Results: Results show no 
statistical significance in colorectal screening utilization before and after January 
2011. The absolute numbers of patients who utilized preventative services in 2009 
(N= 782) and 2011 (N= 776) were comparable. However, fewer MCBS respondents uti-
lized colorectal screening in 2012. ConClusions: Results for years 2009 and 2011 
suggest no impact of the policy changes on the utilization of colorectal screening 
